Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma
PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.
Projectdetails
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a life-threatening disease with few treatment options. Recently, the chemical space for targeted therapeutics was significantly increased by the development of compounds that induce protein degradation (PROTACs), but so far, they are unavailable for PDAC. The main motivation of PROTAC-PDAC is to develop novel targeted therapies for PDAC.
Project Background
The project is based on our accomplishments in three crucial areas:
- My group identified – as target candidates – a series of transcription factors that are absolutely required for PDAC growth in vivo.
- We developed dozens of potent, specific PROTACs, thereby gaining deep insight into the underlying design principles and synthesis procedures.
- We established genetic models in mice for simulating PROTAC function and discovering ideal target–E3 ligase pairs.
Project Aims
In PROTAC-PDAC, we will develop compounds that degrade key oncogenic transcription factors and inhibit pancreatic tumor growth with minimal toxicity in healthy tissues.
Aim I
We will start by implementing the Auxin degron system in a murine PDAC model to induce degradation of the target candidates and select four priority targets with the highest therapeutic index.
Aim II
Then, we will assess their oncogenic functions by analyzing molecular, cellular, and organismic consequences of acute depletion in mice.
Aim III
In parallel, we will develop pharmaceutical PROTACs to induce target degradation and analyze their efficacy in PDAC models.
Aim IV
Finally, with the aim of developing less toxic PDAC therapy, we will identify pancreatic E3 ligases for the design of the first tissue-specific PROTACs that induce target degradation primarily in pancreatic tumor cells.
Conclusion
While the main goal of PROTAC-PDAC is to develop new PROTAC-based therapeutic strategies, we will also establish groundbreaking methods and models leading to fundamental discoveries in PDAC biology.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.999.401 |
Totale projectbegroting | € 1.999.401 |
Tijdlijn
Startdatum | 1-12-2023 |
Einddatum | 30-11-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIELpenvoerder
- JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approachTrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space. | ERC Starting... | € 1.499.625 | 2022 | Details |
Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapyThis project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer. | ERC Proof of... | € 150.000 | 2022 | Details |
Actionable metabolite supplements to improve treatment response in pancreatic cancerThe ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients. | ERC Proof of... | € 150.000 | 2024 | Details |
KRAS-AlphaTACs: a novel class of biotherapeutics to target KRASThe project aims to develop and pre-clinically validate AlphaTACs for targeted degradation of KRAS proteins to advance cancer therapy and support a new spin-off company. | ERC Proof of... | € 150.000 | 2023 | Details |
Protease Profiling and Triggered Drug Delivery for Personalized Cancer TherapyPROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery. | ERC Consolid... | € 1.842.642 | 2022 | Details |
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach
TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.
Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy
This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.
Actionable metabolite supplements to improve treatment response in pancreatic cancer
The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.
KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS
The project aims to develop and pre-clinically validate AlphaTACs for targeted degradation of KRAS proteins to advance cancer therapy and support a new spin-off company.
Protease Profiling and Triggered Drug Delivery for Personalized Cancer Therapy
PROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYMYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes. | EIC Accelerator | € 2.494.504 | 2023 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic CancerLASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly. | EIC Pathfinder | € 2.988.461 | 2024 | Details |
A novel, first-in-its-kind, aptamer-based LYTACs to address the unmet clinical need of diabetic wounds.APTADEGRAD aims to demonstrate the efficacy of novel aptamer-based LYTACs in healing diabetic foot ulcers by targeting key inflammatory proteins to improve treatment outcomes. | EIC Pathfinder | € 2.321.677 | 2022 | Details |
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.
A novel, first-in-its-kind, aptamer-based LYTACs to address the unmet clinical need of diabetic wounds.
APTADEGRAD aims to demonstrate the efficacy of novel aptamer-based LYTACs in healing diabetic foot ulcers by targeting key inflammatory proteins to improve treatment outcomes.